Brivaracetam not checked

UCB Biopharma SRL · UCB34714

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
3 active
21 in total · 3 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Drug: Brivaracetam Film-coated tablet Pharmaceutical form: Film-coated tablet Route of administration: Oral use Brivaracetam film-coated tablet \[10, 25 or 50 mg\] will be administered twice per day in equal doses.”In the company’s words, NCT06315322 on ClinicalTrials.gov
Tested for
Childhood Absence Epilepsy, Juvenile Absence Epilepsy, Epilepsy
Main trialPhase 3
“The purpose of the study is to investigate the long-term safety and tolerability of brivaracetam in study participants with childhood absence epilepsy or juvenile absence epilepsy.”In the company’s words, NCT06315322 on ClinicalTrials.gov
Other names
BRV · Briviact · UCB34714

Other drugs for Childhood Absence Epilepsy

All 2 drugs for Childhood Absence Epilepsy

Copies tested against it1

Other companies’ versions, mostly cheaper copies for when the patent ends

Coming up2

Changes1

Last 90 days

Trials21

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 16 Nov 2029 A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Phase 3Active, not recruiting 8 Jul 2030 A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
Phase 3Completed Jan 2008 Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
Phase 3Completed Dec 2008 Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
Phase 3Completed Feb 2009 Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures
Phase 3Completed May 2014 Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
Phase 3Completed Sep 2017 This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment
Phase 3Completed 18 Apr 2019 Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy
Phase 3Completed May 2019 Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy
Phase 3Terminated 3 Sep 2020 A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures
Phase 3Completed 27 Mar 2021 A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Phase 3Completed 3 Feb 2022 Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
Phase 3Completed 30 Jun 2022 A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
Phase 3Completed 24 Dec 2024 A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
Phase 3Completed 18 Mar 2025 A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Phase 3Completed 7 Jul 2026 A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
Phase 2Completed 4 Nov 2020 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy
Phase 1Completed 8 Jun 2021 A Study to Evaluate the Pharmacokinetics and Safety of Brivaracetam in Healthy Chinese Subjects
Phase 1Completed 13 May 2022 A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Male Japanese Study Participants
Phase 1Completed 4 Jun 2024 A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants
Phase 3Authorised not given FAST ACUTE SEDATION AT INTENSIVE CARE VS. HIGH-DOSE I.V. ANTI-SEIZURE MEDICATION FOR TREATMENT OF NON-CONVULSIVE STATUS EPILEPTICUS - A RANDOMIZED, MULTICENTER TRIAL (FAST TRIAL)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Brivaracetam

Following is part of Solo: you see every change to Brivaracetam the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in